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Atrial natriuretic peptide (ANP) has a central role in regulating blood pressure in humans. Recently, microRNA 425 (miR-425)
was found to regulate ANP production by binding to the mRNA ofNPPA, the gene encoding ANP. mRNAs typically contain
multiple predicted microRNA (miRNA)-binding sites, and binding of different miRNAsmay independently or coordinately reg-
ulate the expression of any givenmRNA.We used a multifaceted screening strategy that integrates bioinformatics, next-genera-
tion sequencing data, human genetic association data, and cellular models to identify additional functionalNPPA-targeting
miRNAs. Two novel miRNAs, miR-155 andmiR-105, were found to modulate ANP production in human cardiomyocytes and
target genetic variants whose minor alleles are associated with higher human plasma ANP levels. Both miR-155 andmiR-105
repressedNPPAmRNA in an allele-specific manner, with the minor allele of each respective variant conferring resistance to the
miRNA either by disruption of miRNA base pairing or by creation of wobble base pairing. Moreover, miR-155 enhanced the re-
pressive effects of miR-425 on ANP production in human cardiomyocytes. Our study combines computational, genomic, and
cellular tools to identify novel miRNA regulators of ANP production that could be targeted to raise ANP levels, which may have
applications for the treatment of hypertension or heart failure.
Atrial natriuretic peptide (ANP), which is encoded by theNPPA gene, is a cardiac hormone that exhibits diuretic, na-
triuretic, and vasorelaxant activities (1). In the PARADIGM-HF
clinical trial, inhibition of neprilysin (an enzyme that degrades
natriuretic peptides) in combination with renin-angiotensin-al-
dosterone system blockade reduced the number of hospitaliza-
tions for congestive heart failure and deaths from cardiovascular
causes (2). The PARADIGM-HF trial has rekindled interest in the
natriuretic peptide system as a therapeutic target and highlights
the therapeutic importance of identifying factors that may in-
crease endogenous natriuretic peptide levels.
Intravenous administration of ANP lowers blood pressure and
induces natriuresis in animal models and in patients with heart
failure (3). Transgenic mice overexpressing ANP are hypotensive
(4), while ANP-deficient mice are hypertensive (5). However, the
role of ANP in blood pressure regulation in the general population
has remained uncertain until recent population genetic studies
revealed that the minor allele of a common genetic variant
(rs5068) inNPPA is associated with increased plasma ANP levels,
lower blood pressure, and reduced risk of hypertension (6). These
findings support a direct role of ANP in blood pressure regulation
in humans and illustrate that modulating ANP levels could be a
clinically relevant approach to treating hypertension or heart fail-
ure. The rs5068 single nucleotide polymorphism (SNP) is located
in the 3= untranslated region (3=UTR) ofNPPA, where it disrupts
the target binding site of a microRNA (miRNA), miR-425 (7).
Binding of more than one miRNA can independently or coor-
dinatelymodulate the expression of any givenmRNA (8, 9). How-
ever, identifying bona fide miRNAs that regulate an mRNA of
interest has been challenging. Although computational prediction
algorithms are helpful in generating lists of potential miRNA can-
didates, the lists often contain a substantial number of false-posi-
tive miRNAs, which do not actually regulate the target mRNA
(10). Due to the poor predictive accuracy of these algorithms, it is
difficult to discern which of the candidate miRNAs warrant fur-
ther experimental validation.
In the current study, we sought to identify additional miRNAs
that target the NPPA 3= UTR. We used a sequential screening
strategy that involved (i) in silico prediction ofmiRNA candidates,
(ii) prioritization of candidates based on (a) miRNA expression
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data in human atrial tissues and/or (b) the presence of common
genetic variants within the predicted miRNA binding site that are
associated with circulating ANP levels in human population ge-
netics studies, (iii) experimental validation of the predicted inter-
actionwithNPPAmRNAusing luciferase reporter assays, and (iv)
confirmation of the effect of the miRNA on NPPA mRNA levels
and ANP protein levels in human cardiomyocytes.
MATERIALS AND METHODS
In silico analysis. The microRNA Data Integration Portal (mirDIP) (11)
was used to generate a list ofmiRNAs that are predicted in silico to interact
with the NPPA 3= UTR (NM_006172). The mirDIP (version 1.1.2) was
run with the default settings.
Cell culture. COS-7 cells (American Type Culture Collection) were
cultured inDulbecco’smodified Eagle’smedium (Life Technologies) sup-
plemented with 10% fetal calf serum, 2 mM L-glutamine, 200 U/ml pen-
icillin, and 200g/ml streptomycin (Fisher Scientific).Human cardiomy-
ocytes were differentiated from human embryonic stem cells (hESCs) as
follows: hESCs from the WA07 (H7) cell line were cultured on Matrigel-
coated tissue culture polystyrene plates and maintained in mTeSR1 me-
dium (Stem Cell Technologies). hESC medium was refreshed every 24 h,
and hESCs were passaged using dispase (Sigma-Aldrich) at confluence.
Cardiac differentiation of hESCs was induced using small molecules as
previously described (12). Briefly, when hESCs maintained on Matrigel
plates achieved confluence, cells were treated with CHIR99021 (Stem-
gent) in RPMI medium (Life Technologies) supplemented with Gem21
NeuroPlex without insulin (Gemini Bio Products) for 24 h (from day 0 to
day 1). The mediumwas replaced with RPMImedium-Gem21–insulin at
day 1. The cells were then treated with IWP4 (Stemgent) in RPMI medi-
um-Gem21–insulin at day 3, and themediumwas refreshed on day 5 with
RPMI medium-Gem21–insulin. Cells were maintained in RPMI supple-
mented with Gem21 NeuroPlex (Gemini Bio Products) starting from day
7, with the medium changed every 3 days. Beating clusters were seen
starting from day 10 of differentiation. Cardiomyocytes were harvested 5
to 10 days after the onset of beating, typically from day 15 to 20 of differ-
entiation. For dissociation, cardiomyocytes were treated with collagenase
A and B (Roche) in RPMI medium-Gem21 for 15 min. Afterward, the
collagenase solution was removed from the cardiomyocytes and replaced
with 0.05% trypsin-EDTA (Life Technologies) for a 3-min treatment to
obtain single cells. Trypsin was neutralized with RPMI medium-Gem21,
and cardiomyocyteswere centrifuged and resuspended inRPMImedium-
Gem21 for plating. Expression of cardiac troponin T was confirmed in all
experiments. Cardiomyocytes were confirmed by sequencing to be ho-
mozygous for the rs5068, rs61764044, and rs5067 major alleles.
miRNA mimics and inhibitors. Chemically modified, double-
strandedRNAsdesigned tomimic endogenousmaturemiRNAs, aswell as
a scrambled negative-control miRNA mimic, were purchased from Life
Technologies. Throughout this work, miRNA is used to indicate miRNA
mimic when exogenously administered. Chemically modified single-
stranded RNA designed to inhibit endogenous mature miRNAs (anti-
miRs) and a single-stranded scrambled negative-control anti-miRNA
were also purchased from Life Technologies.
Generation of luciferase-NPPA 3= UTR reporter constructs. The
NPPA 3= UTR sequence (299 bp) including the major alleles of rs5068,
rs5067, and rs61764044 was PCR amplified from a deidentified human
HapMap genomicDNA sample obtained fromCoriell Repositories (Cori-
ell Institute for Medical Research). The PCR product was cloned into the
pIS0 vector (Addgene) 3= of the sequence encoding firefly luciferase to
generate the wild-type luciferase construct (WT-Luc). In addition, mu-
tated NPPA 3= UTR luciferase constructs were created by site-directed
mutagenesis using the QuikChange II XL site-directed mutagenesis kit
(Stratagene) and synthetic oligonucleotides (Life Technologies) accord-
ing to themanufacturers’ protocols. The synthetic oligonucleotides used
to generate the 155 Mut-Luc construct were 5=-CCTCGCCTCTCCCA
CCCCATCGTGGCAATTTTAAGGTAGAACCTC-3= and 5=-GAGGT
TCTACCTTAAAATTGCCACGATGGGGTGGGAGAGGCGAGG-3=.
The synthetic oligonucleotides used to generate the rs61764044 Mi-
nor-Luc construct were 5=-GCCTCTCCCACCCCACGCATTAAATT
TTAAG-3= and 5=-CTTAAAATTTAATGCGTGGGGTGGGAGAGG
C-3=. The synthetic oligonucleotides used to generate the rs5067
Minor-Luc construct were 5=-GGTCTCTGCTGCATTCGTGTCATCT
TGTTGC-3= and 5=-GCAACAAGATGACACGAATGCAGCAGAGAC
C-3=. The synthetic oligonucleotides used to generate the 103/107
Mut-Luc construct were 5=-CTCCTGTCCCCTGGGGTCTCAACGC
GATTTGTGTCATCTTGTTGC-3= and 5=-GCAACAAGATGACACA
AATCGCGTTGAGACCCCAGGGGACAGGAG-3=.
Transient transfection of luciferase constructs andmiRNAs or anti-
miRs intoheterologous cells.COS-7 cellswere transfectedwithwild-type
or mutated luciferase-NPPA 3= UTR constructs using X-tremeGENE HP
DNA transfection reagent (Roche) according to the manufacturer’s pro-
tocol. Twenty-four hours after transfection of the constructs, mirVana
miRNA mimics (5 nM), scrambled negative-control miRNA mimic (5
nM), anti-miRNA inhibitors (100 nM), or scrambled negative-control
anti-miR (100 nM) were transfected using Lipofectamine RNAiMax (Life
Technologies). (For miRNA transfection using two miRNA mimics, the
total amount of transfected miRNA was held constant under all experi-
mental conditions. For the experimental conditions labeled with “miR-
425” or “miR-155,” the total concentration of transfected miRNA was
held constant by the addition of the scrambled negative-control miRNA
mimic. For anti-miRNA cotransfection, the total amount of transfected
anti-miR was held constant under all experimental conditions. For the
experimental conditions labeled with “anti-miR-425” or “anti-miR-155,”
the total concentration of transfected miRNA was held constant by the
addition of the scrambled negative-control anti-miRNA.) After an addi-
tional 48 h, firefly and renilla luciferase activities in cell extracts were
measured using the Dual-Luciferase reporter assay system (Promega).
Transient transfection ofmiRNAs or anti-miRNAs into hESC-CMs.
hESC-derived cardiomyocytes (hESC-CMs) were transfected with either
miRNA mimic (50 nM), scrambled negative-control miRNA mimic (50
nM), anti-miRNA (100 nM), or scrambled negative-control anti-miRNA
(100 nM) using Lipofectamine RNAiMax. (For miRNA cotransfection,
the total amount of transfected miRNA was held constant under all ex-
perimental conditions. For the experimental conditions labeled with
“miR-425” or “miR-155,” the total concentration of transfected miRNA
was held constant by the addition of the scrambled negative-control
miRNAmimic.) After 24 h, cells werewashed and incubated in serum-free
medium for an additional 24 h. NPPA gene expression was measured
using quantitative reverse transcription-PCR (qRT-PCR), and ANP pro-
tein production and secretion were assessed using an enzyme-linked im-
munosorbent assay (ELISA) (proANP 1-98; BiomedicaMedizinprodukte
GmbH & Co KG) to detect N-terminal-proANP (Nt-proANP) levels in
culture medium.
Transient transfectionofNPPA cDNAexpressionplasmidandmiR-
105 or anti-miR-105 into heterologous cells.A full-length humanNPPA
cDNA expression plasmid containing the rs5067 major allele (OriGene;
catalogue no. SC122740) and a plasmid specifying renilla luciferase (as a
transfection efficiency control) were transfected into COS-7 cells using
X-tremeGENE HP DNA transfection reagent. Twenty-four hours after
transfection of the constructs, miR-105 mimic (5 nM), scrambled nega-
tive-control miRNA mimic (5 nM), anti-miR-105 (100 nM), or scram-
bled negative-control anti-miRNA (100 nM) was transfected using Lipo-
fectamine RNAiMax. Cells and culture medium were collected 24 h after
miRNA or anti-miRNA transfection formeasurement of renilla luciferase
activity and secreted Nt-proANP levels by ELISA, respectively.
Measurement ofmRNA andmiRNA levels.Total RNAwas extracted
from cultured cells using TRIzol (Life Technologies), and cDNAwas syn-
thesized using the high-capacity cDNA reverse transcription kit (Applied
Biosystems) according to the manufacturer’s protocol.NPPA and glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH)mRNA levels weremea-
sured by qRT-PCR using TaqMan assays (Applied Biosystems) in a 7500
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Fast real-time PCR system (Life Technologies) according to themanufac-
turer’s protocol. Relative changes in NPPA mRNA levels normalized to
GAPDHmRNA levels were determined using the relative cycle threshold
(CT) method. TaqMan miRNA reverse transcription and real-time assay
kits (Applied Biosystems) were used to detect mature miRNAs and U6
small nuclear RNA (U6 snRNA). Relative changes in miRNA levels nor-
malized to U6 snRNA levels were determined using the relative CT
method.
Human population genetic analysis. The midregional fragment of
proANP (MR-proANP) was measured in plasma samples from the
Malmö Diet and Cancer Study using an immunoluminometric assay
(BRAHMS), as previously described (13). Genotypes were generated us-
ing a genome-wide SNP microarray (Illumina Omni Express Exome; Il-
lumina).MR-proANP showed right-skewed distributions and underwent
natural logarithmic transformation (lnMR-proANP) before analysis. Ge-
netic association was tested using linear regression with an additive ge-
netic model adjusted for age and sex.
Statistical analysis. For all figures, data are presented as means 
standard errors of the means (SEMs) from 6 biological replicates (n 6),
and statistical significance was assessed by two-tailed independent t test
and one-way analysis of variance (ANOVA) with Bonferroni post hoc
testing, as appropriate. In all cases, a P value of 0.05 was considered
statistically significant. t tests are reported without adjustments for mul-
tiple comparisons. Each experimentwas repeated at least three times, with
consistent results. Representative figures are presented in this work.
RESULTS
miRNAs predicted to target theNPPA 3=UTR. ThemirDIP (11)
was used to generate a list ofmiRNAs predicted in silico to interact
with theNPPA 3=UTR. The 7 algorithms inmirDIP use a number
of criteria to identify potential miRNA-mRNA interactions, in-
cluding base pairing with the seed sequence (i.e., nucleotides 2 to
8 at the miRNA 5= end), evolutionary conservation of target sites,
thermal stability of the miRNA-mRNA duplex, and secondary
structure surrounding the miRNA binding site (14). Four hun-
dred ninety-four miRNAs were predicted to target the NPPA 3=
UTR by at least one of the 7 mirDIP algorithms, and 37 miRNAs
were predicted to interact with theNPPA 3= UTR by 3 or more of
the algorithms (Fig. 1). Thirty of the 37miRNAswere expressed in
human atrial tissues (15). We were interested in the miRNAs that
were expressed in the atria because ANP is synthesized predomi-
nantly in the atria (1). As expected, miR-425 was among the 30
miRNAs predicted to target NPPA. We focused our attention on
12 of the remaining 29 miRNAs because they were expressed at
high levels in human atrial tissues (15). Seed binding sites of 3 of
these 12miRNAs were predicted to include common genetic vari-
ants, either SNPs (miR-155 and miR-769-5p) or an insertion-
deletion (miR-497-3p), in the NPPA 3= UTR (see Table S1 in the
supplemental material).
Despite lower expression of miR-105 in human atrial tissue
(15), this miRNA was included as a 13th potential candidate
NPPA-modulatingmiRNA because the seed sequence ofmiR-105
spans a genetic variant in theNPPA 3=UTR (see Fig. S1A andD in
the supplemental material) that is associated with plasma Nt-
proANP levels in humans (see below).
To test the predicted interaction of each of the 13 candidate
miRNAs with the NPPA 3= UTR, we generated a reporter con-
struct in which the firefly luciferase gene was ligated to the wild-
type NPPA 3= UTR (WT-Luc). The WT-Luc construct and a sec-
ond plasmid directing constitutive expression of renilla luciferase
to control for transfection efficiency were cotransfected with each
of the candidate miRNAs into COS-7 cells. Of the 13 candidate
miRNAs, miR-155, miR-103, miR-107, and miR-105 each re-
duced the luciferase activity in cells containing the WT-Luc con-
struct (Fig. 2), suggesting that these 4miRNAs could interact with
theNPPA 3= UTR. Transfection of the other 9 candidate miRNAs
failed to alter luciferase activity (see Table S1 in the supplemental
material). Therefore, we chose to further investigate the potential
roles of miR-155, miR-103, miR-107, and miR-105 in the regula-
tion of NPPA expression.
Validation of the predicted binding of miR-155 with the
NPPA 3= UTR. To confirm that the predicted seed binding se-
quence for miR-155 was required for the interaction between
miR-155 and the NPPA 3= UTR, a reporter construct (155 Mut-
Luc) in which mutations were introduced in 6 of the NPPA 3=
UTR seed binding nucleotides was generated. Transfection of
miR-155 reduced the luciferase activity in COS-7 cells containing
the wild-type but not the mutant construct (Fig. 3A). We con-
firmed that COS-7 cells express miR-155 (Table 1). To further
establish that miR-155 interacts with theNPPA 3=UTR, we trans-
fected an anti-miRNA directed against miR-155 (anti-miR-155)
together with the wild-type or mutant construct into COS-7 cells.
FIG 1 Schematic workflow for identification of NPPA-targeting miRNAs. In
silico miRNA predictions were based on mirDIP. Evidence of expression in
human atrial tissues was based on the work of Hsu et al. (15).
MicroRNAs Regulate Atrial Natriuretic Peptide Levels
July 2016 Volume 36 Number 14 mcb.asm.org 1979Molecular and Cellular Biology
 o
n








Inhibition of endogenousmiR-155 by anti-miR-155 increased the
luciferase activity in cells containing the wild-type but not the
mutant construct (Fig. 3B). These results suggest that theNPPA 3=
UTR is a direct target ofmiR-155 and that the effect ismediated by
the sequence complementary to the seed sequence.
miR-155 regulates endogenous NPPAmRNA and ANP pro-
tein levels in human cardiomyocytes. To determine whether
miR-155 regulates endogenous NPPA mRNA expression and
ANP protein production in cardiomyocytes, we transfected
miR-155 into human embryonic stem cell-derived cardiomyo-
cytes (hESC-CMs) and evaluated its effect on NPPA mRNA
levels by qRT-PCR and production of the secreted Nt-proANP
protein by ELISA. Transfection of miR-155 into hESC-CMs
reduced endogenousNPPAmRNA (Fig. 4A), as well as secreted
Nt-proANP protein levels (Fig. 4B), while the opposite effects
were obtained with the transfection of anti-miR-155 (Fig. 4C
and D). These findings provide support for the biological rele-
vance of miR-155 in regulating NPPAmRNA and ANP protein
levels in human cardiomyocytes.
Genetic variant rs61764044 is associated with plasma ANP
levels and blood pressure in humans and disrupts miR-155
binding of NPPAmRNA.During the course of studies to identify
additional variants in the NPPA locus, we performed deep se-
quencing analyses on 268 samples from individuals of European
descent and identified SNP rs61764044, which lies in themiR-155
binding site of theNPPA 3=UTR (see Fig. S1C in the supplemental
material); this SNP has also been reported in the 1000 Genomes
Project database. This variant is perfectly correlated with rs5068,
which lies 123 nucleotides upstream in the 3= UTR (see Fig. S1A),
indicating that the minor alleles of rs61764044 and rs5068 are
always inherited together (perfect linkage disequilibrium, r2 1).
Previous studies showed that the rs5068 minor allele disrupts miR-
425 binding and is strongly associatedwith higher plasmaANP levels
and lower blood pressure (6, 7). Because of perfect correlation of the
rs61764044 and rs5068 minor alleles, the rs61764044 minor allele is
associated with increased plasma ANP levels, lower blood pressure,
and reduced risk of hypertension in humans.
The miR-155 seed sequence spans the major allele of
rs61764044, and the minor allele of rs61764044 is predicted to
introduceG-Uwobble base pairingwithin themiR-155 seed bind-
ing region (see Fig. S1C in the supplemental material). G-U wob-
bles in the miRNA seed binding region impair the ability of an
miRNA to repress the mRNA target (16–18). We generated a re-
porter construct (rs61764044 Minor-Luc) in which the firefly lu-
ciferase gene was ligated to theNPPA 3=UTR sequence containing
the minor alleles of both rs61764044 and rs5068. Transfection of
FIG 2 FourmiRNAs predicted in silico to target theNPPA 3=UTR reduce the luciferase activity produced by the firefly luciferase-NPPA 3=UTR (WT-Luc) construct.
The ratio of firefly luciferase activity to renilla luciferase activity was normalized to the ratio in COS-7 cells transfected with constructs encoding luciferase without the
NPPA 3= UTR and renilla. The effect of each miRNA was compared to that of a scrambled negative-control miRNAmimic (relative luciferase activity). miR-155 (A),
miR-103 (B),miR-107 (C), andmiR-105 (D) reduced the activity of theWT-Luc construct.Data aremeansSEMs (n6biological replicates; two-tailed independent
t test).
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miR-155 reduced the luciferase activity in COS-7 cells contain-
ing the major allele (WT-Luc) construct but not the minor
allele construct (Fig. 3A). Anti-miR-155 increased the lucifer-
ase activity in COS-7 cells containing the major but not minor
allele construct (Fig. 3B). Taken together, these results indicate
that the NPPA 3= UTR containing the rs61764044 major allele
is a direct target of miR-155 and that the presence of the
rs61764044 minor allele confers resistance to miR-155-medi-
ated repression.
miR-155 augments the miR-425-mediated decreases in
endogenous NPPA mRNA and ANP protein levels in human
cardiomyocytes. Given the fact that rs61764044 is perfectly cor-
related with rs5068 and previous studies demonstrated that miR-
425 targets the NPPA 3= UTR with the rs5068 major allele and
inhibits ANP levels in human cardiomyocytes (7), we sought to
determine whether miR-155 can enhance the repressive effects of
miR-425 on the NPPA mRNA. Transfection of either miRNA
alone reduced the luciferase activity in the presence of theWT-Luc
construct containing the major alleles of rs61764044 and rs5068
but not the rs61764044 Minor-Luc construct containing the mi-
nor alleles of rs61764044 and rs5068 (Fig. 5A). Cotransfection of
miR-425 andmiR-155 decreased luciferase activity in the presence
of the WT-Luc construct containing the major alleles but not the
rs61764044 Minor-Luc construct containing the minor alleles of
rs61764044 and rs5068 (Fig. 5A). Cotransfection of anti-miR-425
and anti-miR-155 increased the luciferase activity in the presence
of the WT-Luc construct containing the major alleles but not the
rs61764044 Minor-Luc construct containing the minor alleles of
rs61764044 and rs5068 (Fig. 5B). Moreover, in hESC-CMs,
cotransfection of miR-425 and miR-155 decreased endogenous
NPPA mRNA levels and secreted Nt-proANP protein levels to a
greater extent than did either miRNA alone (Fig. 5C and D).
Taken together, these findings indicate that miR-155 regulates
NPPA expression and ANP protein production through its inter-
action with the rs61764044 major allele and can act together with
miR-425 to further suppress ANP levels. Thus, association of the
rs5068 and rs61764044minor alleles with higher plasma ANP and
Nt-proANP levels, as well as lower blood pressure and reduced
risk of hypertension in humans, is likely due to coinheritance of
resistance to two independent miRNAs (6, 7).
miR-103 and miR-107 do not appear to regulate NPPA
mRNAandANPprotein levels inhumancardiomyocytes.Of the
13 candidate miRNAs, miR-103 andmiR-107 share the same seed
FIG 3 miR-155 interacts with theNPPA 3= UTR in an rs61764044 allele-specific
manner. (A) miR-155 reduced the activity of the WT-Luc construct but not the
155Mut-Lucconstruct (containinga6-nucleotidemutationat thepredictedmiR-
155 seed binding site) or the rs61764044Minor-Luc construct. The ratio of firefly
luciferase activity to renilla luciferase activitywasnormalized to the ratio inCOS-7
cells transfected with constructs encoding luciferase without the NPPA 3= UTR
and renilla. For each construct (WT-Luc, 155 Mut-Luc, or rs61764044 Minor-
Luc), the effect of the miRNA was compared to that of a scrambled negative-
control miRNA mimic (relative luciferase activity). (B) Anti-miR-155 increased
the activity of the WT-Luc construct but not the 155 Mut-Luc construct or the
rs61764044 Minor-Luc construct. The ratio of firefly luciferase activity to renilla
luciferase activity was normalized to the ratio inCOS-7 cells transfectedwith con-
structs encoding luciferase without the NPPA 3= UTR and renilla. For each con-
struct (WT-Luc, 155 Mut-Luc, or rs61764044 Minor-Luc), the effect of the anti-
miR was compared to that of a scrambled negative-control anti-miRNA (relative
luciferase activity). The rs61764044 Minor-Luc construct contains the minor al-
leles of both rs61764044 and rs5068. Data are means SEMs (n 6 biological
replicates; two-tailed independent t test).
TABLE 1 Summary of data relating to miR-425, miR-155, miR-105, miR-103, and miR-107a
miRNA







Human population genetics studies:












miR-425 111 11 11 2 1 2 1 rs5068
miR-155 11 111 11 2 1 2 1 rs61764044
miR-105 1 1 1 2 1 — 1 rs5067
miR-103 111 111 111 2 1 — — —
miR-107 11 11 1 2 1 — — —
a Expression levels in human atrial tissues are based on RNA sequencing data in the work of Hsu et al. (15). Expression levels in COS-7 cells and hESC-CMs were determined by
qRT-PCR (1, low;11, intermediate;111, high). For effect of miRNA/anti-miRNA in luciferase assays,1 indicates an increase and2 indicates a decrease in luciferase
activity in cells containing the WT-Luc construct. For effect of miRNA/anti-miRNA in hESC-CMs,1 indicates an increase and2 indicates a decrease in NPPAmRNA and
secreted Nt-proANP protein levels. —, none.
MicroRNAs Regulate Atrial Natriuretic Peptide Levels
July 2016 Volume 36 Number 14 mcb.asm.org 1981Molecular and Cellular Biology
 o
n








sequence and thus are predicted to target the same complemen-
tary sequence in the NPPA 3= UTR (see Fig. S1A and E in the
supplemental material). Exogenous administration of either
miRNA reduced the luciferase activity in COS-7 cells containing
the wild-type construct but not a construct (103/107 Mut-Luc)
with a mutated seed binding site (see Fig. S2A and S3A in the
supplemental material), confirming that the seed binding site is
required for interaction of miR-103 and miR-107 with the NPPA
3=UTR. Inhibition of endogenousmiR-103 ormiR-107with their
respective anti-miRNAs increased the luciferase activity in COS-7
cells containing the wild-type but not mutant construct (see Fig.
S2B and S3B). These findings indicate that the NPPA 3= UTR is a
direct target of miR-103 and miR-107.
Human ESC-CMs express both miR-103 and miR-107 (Table
1). The effects of overexpressing miR-103 and miR-107, as well as
each of their anti-miRNAs, on NPPA mRNA and ANP protein
levels were examined. Transfection of the miRNAs or their anti-
miRNAs had no effect on NPPA mRNA or secreted Nt-proANP
protein levels in hESC-CMs (data not shown). These findings sug-
gest that these miRNAs may not have a role in regulating endog-
enous ANP levels in human cardiomyocytes.
Genetic variant rs5067 is associatedwith plasmaNt-proANP
levels in humans and disrupts miR-105 binding of NPPA
mRNA. MicroRNA-105 was considered a candidate NPPA-tar-
geting miRNA for further investigation because a common poly-
morphism (rs5067) lies in the miR-105 binding site (see Fig. S1A
and D in the supplemental material). The miR-105 seed sequence
binds to the rs5067 major allele, but the rs5067 minor allele is
predicted to disrupt base pairing of miR-105 with the NPPA 3=
UTR. In a study of 5,453 Swedish individuals in the Malmö Diet
and Cancer Study, the rs5067 minor allele was found to be asso-
ciated with higher plasma Nt-proANP levels (0.079 standard de-
viations of lnMR-proANP per G-allele of rs5067, 95% confidence
intervals  0.024 to 0.135, P  0.004). The mean and standard
deviation of lnMR-proANP are 4.20 and 0.416. The correlation of
rs5067 with rs5068 is low (r2  0.012, HapMap CEU), although
with high linkage disequilibrium (D= 1) due to the fact that the
haplotypes containing the minor alleles of the two variants are
mutually exclusive (i.e., the minor alleles are never coinherited).
The variants rs5067 and rs5068 are thus independent genetic as-
sociation signals with plasmaNt-proANP levels.We hypothesized
that disruption of the binding of miR-105 to theNPPA 3=UTR by
the rs5067 minor allele could represent a mechanism by which
rs5067 is associated with plasma Nt-proANP levels in humans.
To test whether the presence of the rs5067 minor allele alters
interaction of miR-105 with the NPPA 3= UTR, we performed
luciferase reporter assays using constructs including either the
major or the minor rs5067 allele in COS-7 cells. Transfection of
FIG 4 miR-155 reduces and anti-miR-155 increasesNPPAmRNA and secretedNt-proANP protein levels in human cardiomyocytes. hESC-CMs (1 105 per
well) were transfected with miR-155, a scrambled negative-control miRNA mimic, anti-miR-155, or a scrambled negative-control anti-miRNA. Twenty-four
hours later, cells were washed and incubated in 1 ml of medium. After an additional 24 h, cells andmedia were harvested. (A)NPPAmRNA levels in hESC-CMs
transfected with miR-155 relative to cells transfected with negative-control miRNA mimic. (B) Nt-proANP protein levels (nanomoles/liter) in the medium of
hESC-CMs transfected with miR-155 relative to negative-control miRNAmimic. (C)NPPAmRNA levels in hESC-CMs transfected with anti-miR-155 relative
to negative-control anti-miRNA. (D) Nt-proANP protein levels in the medium of hESC-CMs transfected with anti-miR-155 relative to negative-control
anti-miRNA. Data are means SEMs (n 6 biological replicates; two-tailed independent t test).
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miR-105 reduced the luciferase activity in the presence of theWT-
Luc construct containing the rs5067 major allele but not the con-
struct containing the rs5067minor allele (Fig. 6A).We confirmed
that COS-7 cells express miR-105 (Table 1). Anti-miR-105 in-
creased the luciferase activity in the presence of the WT-Luc con-
struct containing the rs5067 major allele but not the construct
containing the rs5067minor allele (Fig. 6B). Taken together, these
results suggest that theNPPA 3=UTR containing the rs5067major
allele is a direct target of miR-105. The presence of the rs5067
minor allele confers resistance to miR-105-mediated repression,
which could be a mechanism by which rs5067 alters ANP levels in
humans.
miR-105 regulates endogenous NPPA mRNA and ANP pro-
tein levels in human cardiomyocytes. Human ESC-CMs, ho-
mozygous for the rs5067 major allele, were transfected with miR-
105 to determine whether miR-105 can regulate endogenous
NPPA mRNA expression and ANP production. Transfection of
miR-105 had no effect on NPPA mRNA (Fig. 7A) or secreted
Nt-proANPprotein levels (Fig. 7B) in hESC-CMs. As with human
atrial tissues (15), hESC-CMs express miR-105 (Table 1). Inhibi-
tion of endogenous miR-105 with anti-miR-105 did increase
NPPA mRNA (Fig. 7C), as well as secreted Nt-proANP protein
levels (Fig. 7D), in hESC-CMs. Although overexpression of miR-
105 did not have an effect onNPPAmRNAorNt-proANPprotein
levels in hESC-CMs, inhibition of endogenousmiR-105with anti-
miR-105 increased NPPA mRNA and secreted Nt-proANP pro-
tein levels, suggesting that endogenous levels of miR-105 could
modulate NPPA mRNA and ANP protein levels in human cardi-
omyocytes.
DISCUSSION
In this study, we used a multifaceted screening strategy that com-
bined in silicomiRNA target prediction, miRNA expression data,
human genetic association data, and cellular models to identify
four miRNAs, in addition to miR-425, that target the NPPA 3=
UTR. Two of the four miRNAs (miR-155 and miR-105) were
shown to have a functional role inmodulating endogenousNPPA
mRNA levels and secretedNt-proANP levels in human cardiomy-
FIG 5 miR-155 interacts with the rs61764044 major allele and acts together with miR-425 to further suppress NPPAmRNA and ANP protein levels in human
cardiomyocytes. (A andB)Allele-specific effects ofmiR-425 plusmiR-155 (A) and anti-miR-425 plus anti-miR-155 (B) on the luciferase activity produced by the
WT-Luc and rs61764044 Minor-Luc constructs in COS-7 cells. The rs61764044 Minor-Luc construct contains the minor alleles of rs61764044 and rs5068. (C)
NPPAmRNA levels in hESC-CMs transfected with the indicated miRNAs relative to scrambled negative-control miRNAmimic. (D) Nt-proANP protein levels
in the medium of hESC-CMs transfected with the indicated miRNAs relative to scrambled negative-control miRNA mimic. For miR-425 plus miR-155
cotransfection, the total amount of transfected miRNA was held constant under all experimental conditions (10 nM total concentration in COS-7 cells, 100 nM
total concentration in hESC-CMs). For the conditions labeled with “miR-425” or “miR-155,” the total concentration of transfected miRNA was held constant
by the addition of the scrambled negative-control miRNA mimic. For anti-miR-425 plus anti-miR-155 cotransfection, the total amount of transfected anti-
miRNA was held constant under all experimental conditions (200 nM total concentration in COS-7 cells). For the experimental conditions labeled with
“anti-miR-425” or “anti-miR-155,” the total concentration of transfected miRNA was held constant by the addition of the scrambled negative-control anti-
miRNA. Data are means SEMs (n 6 biological replicates). P values are from a two-tailed independent t test. *, P 0.001 versus miR-425, and #, P 0.001
versus miR-155, by one-way ANOVA with Bonferroni post hoc testing.
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ocytes (Table 1; see also Fig. S4 in the supplemental material). We
observed that a genetic variant (rs61764044), which disrupts the
miR-155 binding site, contributes to the ANP-raising and blood
pressure-lowering effects of the previously published rs5068 vari-
ant (6, 7) by virtue of perfect linkage disequilibrium with rs5068.
Similarly to miR-425 and miR-155, miR-105 interacts with a ge-
netic variant (rs5067), specifically binding to the rs5067major but
notminor allele, consistent with the finding that the rs5067minor
allele is associated with increased plasma Nt-proANP levels in
humans. Thus, by integrating computational, genomic, and cellu-
lar approaches, we have identified novel regulatory mechanisms
controlling ANP levels and highlighted the potential of applying a
similar integrated screening strategy to uncover miRNA regula-
tors of other genes of interest.
In silico analysis revealed that as many as 494 miRNAs are pre-
dicted to target theNPPA 3= UTR. Because miRNA-mRNA inter-
actions predicted by multiple algorithms appear to provide
greater specificity without excessive loss of sensitivity (14, 19),
miRNAs predicted to interact with theNPPA 3= UTR by at least 3
of the algorithms were given priority. To further narrow down the
list of miRNAs for subsequent experimental validation, we fo-
cused onmiRNAs that are expressed at abundant levels in human
atrial tissues (15), where the target geneNPPA is highly expressed.
This strategy identifiedmiR-155 as a novelmiRNA that interacted
with theNPPA 3=UTR, as confirmed by luciferase reporter assays,
and decreasedNPPAmRNAand secretedNt-proANPprotein lev-
els in hESC-CMs. AlthoughmiR-103 andmiR-107were also iden-
tified as miRNAs that can target theNPPA 3=UTR based on lucif-
erase reporter assays, neither the miRNAs nor their anti-miRNAs
altered NPPA expression in hESC-CMs, the cell type of interest
(Table 1). Examination of the levels of miR-103 and miR-107 in
COS-7 cells and hESC-CMs transfected with the respective
miRNA mimics showed that compared to the endogenous
miRNA levels in cells transfected with the negative control, there
were similar levels of overexpression of the transfectedmiRNAs in
COS-7 cells (see Fig. S5C andD in the supplementalmaterial) and
in hESC-CMs (see Fig. S6C and D in the supplemental material).
(COS-7 cells and hESC-CMs transfected with miR-425, miR-155,
and miR-105 also showed similar levels of overexpression of each
of the miRNAs compared to cells transfected with the negative
control [see Fig. S5 and S6].) As such, differences in the responses
obtained for miR-103 and miR-107 in the COS-7 cells and hESC-
CMs are most likely not due to differences in the levels of overex-
pression of these transfected miRNAs in the two cell types. A role
for miR-103 and miR-107 in regulating endogenous NPPA ex-
pression in the heart therefore remains unproven and requires
further investigation. Others have also reported instances in
which an miRNA was shown to target a 3= UTR of interest in
luciferase reporter assays but had no effects on endogenous target
mRNA/protein levels in the cell type of interest (20). It has been
proposed that target secondary structure (21, 22) and the presence
of RNA-binding proteins (23, 24), the levels of which may vary
between different cell types, can influence the ability ofmiRNAs to
regulate targetmRNAs and interfere with the ability ofmiRNAs to
directly interact with the 3= UTR of target mRNAs.
In addition to prioritizingmiRNAs that are highly expressed in
human atria, we leveraged human population genetic data to in-
vestigate whether any of the candidate miRNAs were predicted to
target variants in the NPPA 3= UTR that are associated with
plasma ANP levels in humans. This approach led to the identifi-
cation of miR-105, which was validated to interact with rs5067 in
an allele-dependent manner. The rs5067 minor allele disrupted
base pairing betweenmiR-105 and theNPPA 3=UTR,which could
underlie the observed association of the rs5067 minor allele with
higher plasma Nt-proANP levels in humans. The cause of the
failure of miR-105 to decreaseNPPAmRNA and protein levels in
hESC-CMs is unclear and warrants further investigation, but a
potential explanation is that the levels of miR-105 in cardiomyo-
cytes, albeit low (Table 1), may at endogenous levels already exert
FIG 6 miR-105 interacts with the NPPA 3= UTR in an rs61764044 allele-
specificmanner. (A)miR-105 reduced the activity of theWT-Luc construct
but not the rs5067 Minor-Luc construct. The ratio of firefly luciferase
activity to renilla luciferase activity was normalized to the ratio in COS-7
cells transfected with constructs encoding luciferase without the NPPA 3=
UTR and renilla. For each construct (WT-Luc or rs5067 Minor-Luc), the
effect of the miRNA was compared to that of a scrambled negative-control
miRNA mimic (relative luciferase activity). (B) Anti-miR-105 increased
the activity of the WT-Luc construct but not rs5067 Minor-Luc construct.
The ratio of firefly luciferase activity to renilla luciferase activity was nor-
malized to the ratio in COS-7 cells transfected with constructs encoding
luciferase without the NPPA 3= UTR and renilla. For each construct (WT-
Luc or rs5067 Minor-Luc), the effect of the anti-miRNA was compared to
that of a scrambled negative-control anti-miRNA (relative luciferase activ-
ity). Data are means  SEMs (n  6 biological replicates; two-tailed inde-
pendent t test).
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a maximal effect on the targetNPPAmRNA. It has been reported
that the threshold for saturation of miRNA activity varies for dif-
ferent miRNAs, independent of the expression levels of the
miRNA (25, 26). In this model, introducing more miR-105 into
the hESC-CMs would not have any further effect, but inhibiting
endogenous miR-105 would have an effect on NPPA expression
by relieving the repression mediated by endogenous miR-105. In
COS-7 cells transfected with an NPPA cDNA expression plasmid
containing the rs5067 major allele, we observed that cotransfec-
tion of miR-105 reduced secreted Nt-proANP protein levels (see
Fig. S7A in the supplemental material), while the opposite effect
was obtained with cotransfection of anti-miR-105 (see Fig. S7B).
These results suggest that the repressive effect of overexpressing
miR-105 on ANP production can be revealed when the target
NPPA mRNA is also overexpressed, providing support for the
possibility of saturation.
While miR-155 was predicted to target the NPPA 3= UTR and
was expressed in human atria, we discovered the rs61764044 vari-
ant in the miR-155 binding site only when additional sequencing
identified the variant. The perfect correlation between rs5068 and
rs61764044 was not known at the time of the prior studies of
rs5068 (6, 7). The finding of an allele-specific negative regulatory
effect of miR-155 in the current study indicates that rs61764044
contributes to the association between rs5068 and plasma ANP
levels, as well as blood pressure. Furthermore, our results high-
light the importance of having a complete catalogue of genetic
variation. In this model, the presence of the coinherited minor
alleles prevents both miR-425 and miR-155 from binding to the
NPPA 3= UTR, resulting in increased ANP production, lower sys-
tolic and diastolic blood pressures, and reduced risk of hyperten-
sion in humans. The rs61764044 minor allele creates a G-U wob-
ble base pairing in the miR-155 seed binding site. Studies have
shown that the presence of even a single G-U wobble in the seed
binding region impairs miRNA-mediated repression of the
mRNA target (16–18). In the case of the FGF20 3=UTR, for exam-
ple, a similar disruption of a seed binding site was reported for the
T allele of rs12720208, which introduces a G-U wobble base pair-
ing in the miR-433 seed binding site and disrupts the ability of
miR-433 to repress FGF20 (27).
The observation that cotransfection of miR-425 and miR-155
resulted in greater NPPA gene repression in hESC-CMs than did
transfection of either miRNA alone has implications for the ther-
apeutic potential of using combinations of anti-miRNAs to in-
crease ANP levels. In fact, coinheritance of the rs5068 and
rs61764044 minor alleles in humans can be viewed as an experi-
ment of nature that demonstrates the physiologic impact of these
FIG7 Anti-miR-105 increasesNPPAmRNAand secretedNt-proANPprotein levels in human cardiomyocytes. hESC-CMs (1 105 perwell) were transfected
with miR-105, a scrambled negative-control miRNA mimic, anti-miR-105, or a scrambled negative-control anti-miRNA. Twenty-four hours later, cells were
washed and incubated in 1 ml of medium. After an additional 24 h, cells and medium were harvested. (A) NPPA mRNA levels in hESC-CMs transfected with
miR-105 relative to negative-control miRNAmimic. (B) Nt-proANP protein levels in the medium of hESC-CMs transfected with miR-105 relative to negative-
control miRNAmimic. (C)NPPAmRNA levels in hESC-CMs transfected with anti-miR-105 relative to negative-control anti-miRNA. (D) Nt-proANP protein
levels in themedium of hESC-CMs transfected with anti-miR-105 relative to negative-control anti-miRNA. Data aremeans SEMs (n 6 biological replicates;
two-tailed independent t test).
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ANP-raising mechanisms on blood pressure and suggests thera-
peutic opportunities to increase ANP levels with potential benefits
in hypertension or heart failure. Recent studies have implicated
the therapeutic potential of miR-155 inhibition in suppressing
cardiac hypertrophy and heart failure (28, 29). Moreover, miR-
155 levels were also reported to be increased in human hearts with
hypertrophy compared to nonhypertrophic controls and in-
creased miR-155 levels were correlated with depressed cardiac
function and increasedwall thickness (29). Our study is the first to
report that miR-155 can target the NPPA 3= UTR to directly reg-
ulate ANP levels in human cardiomyocytes. While miR-155 is a
multifunctional miRNA with multiple targets (30), its effects on
human NPPA expression could contribute to an effect on cardiac
hypertrophy and heart failure.
From our multitiered screening strategy, we observed that of
the 14 candidate miRNAs (including miR-425) that we tested in
ourNPPA 3= UTR luciferase reporter assay, only 5 of them (miR-
425, miR-155, miR-105, miR-103, and miR-107) were able to re-
duce the luciferase activity of the WT NPPA 3= UTR luciferase
reporter construct. Examination of the predicted binding sites
of these 5 miRNAs revealed that the binding sites of 4 of these
miRNAs (miR-425, miR-105, miR-103, andmiR-107) are located
close to each other in the NPPA 3= UTR (see Fig. S1A in the sup-
plemental material). As mRNA secondary structure has been re-
ported to affect the ability of miRNAs to target mRNAs (21, 22), it
is reasonable to speculate that this region of theNPPA 3=UTRmay
contain secondary structure elements that increase the accessibil-
ity of these miRNA binding sites, thereby facilitating the interac-
tion between these miRNAs and the NPPA 3= UTR. Additional
work investigating the secondary structure of the NPPA mRNA
will be required to confirm this possibility. Moreover, out of these
5 miRNAs that reduced the luciferase activity of the WTNPPA 3=
UTR luciferase reporter construct, we found that only 3 of them
(miR-425, miR-155, and miR-105) were able to modulate ANP
levels in hESC-CMs. A unique characteristic shared by these 3
miRNAs that is not seen for miR-103 and miR-107 is that miR-
425, miR-155, and miR-105 all target sequences in the NPPA 3=
UTR that include genetic variants that are associated with plasma
ANP levels in humans. Our findings suggest that in attempts to
narrow down the list of candidate miRNAs obtained from com-
putational prediction algorithms, it is worthwhile to consider pri-
oritizing the miRNAs which target genetic variants that are asso-
ciated with phenotypes of interest. Such an approach may help
increase the likelihood that the miRNA will have biological rele-
vance in regulating the endogenous levels of its target mRNA.
Several limitations of the present study merit consideration.
We chose to experimentally validate a subset of predicted NPPA-
targetingmiRNAs based on their expression levels in human atrial
tissues. It remains likely that there are othermiRNAs, expressed at
lower levels in human atria, that can interact with the NPPA 3=
UTR and regulate ANP levels. We have not examined primary
human cardiomyocytes because of technical challenges, including
difficulties associated with obtaining human cardiac tissue, low
cardiomyocyte yields from the isolation process, and inability to
maintain the viability of isolated cardiomyocytes for an extended
period of time (31). However, hESC-CMs have been well charac-
terized and exhibit structural and functional properties of native
human cardiomyocytes (32, 33). Gene expression profiling stud-
ies have also shown that gene expression patterns of cardiac tran-
scription factors and cardiac structuralmarkers (includingNPPA)
in hESC-CMs are consistent with gene expression patterns in hu-
man cardiac tissues (34–36). Moreover, miRNA profiling has
demonstrated that known cardiomyocyte-specific miRNAs are
expressed in hESC-CMs and exhibit the expected expression
pattern (34). These observations suggest that hESC-CMs are a
biologically relevant model for studying the effect of miRNAs
on NPPA mRNA levels and ANP production in the human
heart.
In conclusion, we identified miR-155 and miR-105 as novel
regulators of ANP production. These miRNAs target sequences
including genetic variants that are associated with plasma ANP
levels in humans. Our findings suggest the potential for miRNA-
targeted therapies to increaseANP levels, which could supplement
current therapy that reduces natriuretic peptide degradation. Fur-
ther experiments in animals examining the in vivo effects of anti-
miRNAs in derepressing ANP production (which lie beyond the
scope of this study) would help to characterize phenotypic re-
sponses that will further expand our understanding of the clinical
applications of such treatments.
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